Chromosome 12p Deletions in TEL-AML1 Childhood Acute Lymphoblastic Leukemia Are Associated with Retrotransposon Elements and Occur Postnatally

Joseph L. Wiemels,‡ Jerry Hofmann,‡ Michelle Kang,‡ Rebecca Selzer,§ Roland Green,§ Mi Zhou,‡ Sheng Zhong,‡ Luoping Zhang,¶ Martyn T. Smith,¶ Carmen Marsit,¶ Mignon Loh,¶ Patricia Buffler,¶ and Ru-Fang Yeh†

‡Laboratory for Molecular Epidemiology, Department of Epidemiology and Biostatistics and ‡Department of Pediatrics, University of California San Francisco, San Francisco, California; §Roche Nimblegen Systems, Madison, Wisconsin; ¶Division of Environmental Health Sciences and Division of Epidemiology, School of Public Health, University of California at Berkeley, Berkeley, California; and †Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island

Abstract

TEL-AML1 (ETV6-RUNXI) is the most common translocation in the childhood leukemias, and is a prenatal mutation in most children. This translocation has been detected at a high rate among newborns (~1%); therefore, the rate-limiting event for leukemia seems to be secondary mutations. One such frequent mutation in this subtype is partial deletion of chromosome 12p, trans from the translocation. Nine del(12p) breakpoints within six leukemia cases were sequenced to explore the etiology of this genetic event, and most involved cryptic sterile translocations. Twelve of 18 del(12p) parent sequences involved in these breakpoints were located in repeat regions (8 of these in long interspersed nuclear elements). This stands in contrast with TEL-AML1, in which only 21 of 110 previously assessed breakpoints (19%) occur in DNA repeats (P = 0.0001). An exploratory assessment of archived neonatal blood cards revealed significantly more long interspersed nuclear element CpG methylations in individuals at birth who were later diagnosed with TEL-AML1 leukemia, compared with individuals who did not contract leukemia (P = 0.01). Nontemplate nucleotides were also more frequent in del(12p) than in TEL-AML1 junctions (P = 0.004), suggesting formation by terminal deoxynucleotidyl transferase. Assessment of six archived neonatal blood cards indicated that no del(12p) rearrangements backtracked to birth, although two of these patients were previously positive for TEL-AML1 using the same assay with comparable sensitivity. These data are compatible with a two-stage natural history: TEL-AML1 occurs prenatally, and del(12p) occurs postnatally in more mature cells with a structure that suggests the involvement of retrotransposon instability. [Cancer Res 2008;68(23):9935–44]

Introduction

Acute lymphoblastic leukemia is the most common diagnosis in childhood cancer; and ~22% of children harbor the t(12;21) TEL-AML1 (ETV6-RUNXI) translocation. We and others have found that the TEL-AML1 translocation associated with pediatric leukemia often occurs before birth—a total of 36 patients along with their paired archived neonatal blood spots (ANB cards) were tested with 18 ANB cards demonstrating the fusion gene (50%; refs. 1–4). Twin studies have also shown that concordant leukemias in identical twins are often a result of an in utero TEL-AML1 translocation that spread from one twin to the other (5–8), which led Greaves and colleagues to propose a two-stage model for this leukemia beginning with the translocation before birth. Strikingly, the TEL-AML1 translocation was shown to be quite prevalent among newborns (~1%; ref. 9). This revealed that the t(12;21) translocation was not sufficient for leukemia and that complementary and subsequent mutations are the rate-limiting event.

Along with the translocation, ~70% of TEL-AML1+ leukemias exhibit a loss of the other chromosome 12 (the allele not involved in the translocation). The del(12p) is the most common complementary event, and is likely secondary because it is subclonal to the translocation in some patients (10). More evidence that the del(12p) is secondary to t(12;21) is the variable del(12p) end points among patients with the same TEL-AML1 translocation at both initial diagnosis and relapse (11, 12). Elucidating the timing and mechanism of this rearrangement may contribute to preventive measures for leukemia. A variety of other genetic rearrangements have been recently identified as complementary events to TEL-AML1 using high-density single nucleotide polymorphism arrays, including INK4A/B and PAX5, but each with a much lower prevalence than del(12p) (ref. 13).

Extensive microsatellite mapping of TEL-AML1+/del(12p) patients (14–16), as well as recent investigations using high-density whole-genome single nucleotide polymorphism arrays (13, 17, 18), have supported the idea that TEL is the gene target of the del(12p). TEL has a dimerization domain which is retained in the TEL-AML1 chimeric protein. Both this dimerization domain and the AML1 DNA-binding domain are required for oncogenesis by TEL-AML1 (19–21). The TEL protein can bind and inhibit TEL-AML1, and TEL loss in the presence of del(12p) permits the full oncogenic phenotype.

Although the timing and the structure of TEL-AML1 breakpoints are well characterized, the corresponding breakpoints of the del(12p) have not been described. These breakpoints may occur by an alternate mechanism given that they may take place after birth in a more differentiated cell. It is also possible that the 12p deletions precede the translocation in some patients. Because TEL-AML1+ leukemia is characterized by recombinaactivate gene activity as exhibited by RAG expression and recurrent
rarrangements at Ig and TCR loci (22–25), we hypothesized that such activity might be responsible for secondary rearrangements. The TEL-AML1 translocations themselves display characteristics of random breakage events, e.g., DNA breakpoints are unclustered and do not obviously associate with features such as V(D)J recombinase site sequences or topoisomerase II sites. These observations led us to presume that such rearrangements may occur in earlier precursors than the RAG+ pre-B cells which present with the leukemia (26, 27). In animal models, TEL-AML1 activity results in an expanded precursor pool with some impediment of differentiation (28, 29). We now report on both the structure and the timing of origin of del(12p) in TEL-AML1+ leukemia, using a series of leukemias and their corresponding ANB cards (or Guthrie cards).

Materials and Methods

Study subjects. Patient samples were obtained by the Northern California Childhood Leukemia Study (NCCLS), an epidemiology study focusing on the etiology of childhood leukemia in a 35-county area of Northern and Central California. All work was performed under Institutional Review Board approval, and parents provided consent for use of both diagnostic DNA samples and neonatal Guthrie cards specimens. Patient samples were subjected to a cytogenetic classification protocol as previously described (30). DNA was extracted from all 10 patients by SBS/proteinase K/phenol/chloroform methods as previously described, and patients were assessed for TEL-AML1 translocation using long-distance (LD)-PCR and long-distance inverse (LDI)-PCR (3).

Microarray analysis. A highly dense custom microarray, permitting subkilobase resolution, was used to characterize and isolate the deletion end points. Isothermal probes varying in length and averaging 50 bp were tiled on a masked array synthesized microarray using photo-deprotection methods (Nimblegen Systems, Inc.). Probes (390,000) were tiled along the 38 Mb p-arm of chromosome 12. Leukemic DNA labeled with Cy3 and normal control peripheral blood DNA (consisting of expired blood donor–derived DNA) labeled with Cy5 were competitively hybridized to the microarray. Arrays were scanned with an Agilent two-color scanner.

Probe intensities were extracted from images of hybridized arrays using NimbleScan 2.0 software, and quantile-normalized to remove systematic biases. The sample to reference probe intensity ratios (in log 2) were averaged within nonoverlapping 5 kb windows, and regions of estimated equal copy number were derived using a circular binary segmentation algorithm implemented in the DNAcopy package from R/bioconductor. In addition, Lowess lines were constructed at increasing zoom levels to estimate the breakpoints at a subkilobase resolution to permit attempts at sequencing breakpoints. All genome location information was based on Human Genome Release 18.

Sequencing and backtracking. Chromosome 12p deletions were sequenced at the nucleotide level using both LD-PCR and LDI-PCR. Sequencing of interstitial deletions, meaning a portion of the 12p-arm was lost but both the telomere and centromere retained, was first attempted with LD-PCR. Pairs of primers were synthesized at the two margins of the breakpoint, leading to nested LD-PCR with the PCR buffer and cycling conditions as described (31). In other cases in which the distal portion of chromosome 12p was lost (inclusive of the telomere) with only a single breakpoint evident, LDI-PCR was attempted. In these cases, two pairs of primers were located in opposing directions anchored to the side of the breakpoint. As noted in the Results, nested PCR was used to both increase specificity (by using two sets of primers) and increase the amount of PCR product for sequencing. A more complete description of these sequencing methods has been previously described (32).

Backtracking of del(12p) breakpoints was performed using a two-step nested PCR for maximal sensitivity (PCR primers in Supplementary Table S1). This two-round PCR was first determined to detect single DNA copies of translocation events using mock ANB cards with the addition of cell line cells, which harbor a specific translocation. DNA was isolated from ANB cards using the blood spot protocol of the Qiagen DNA Micro kit. Approximately 250 ng of DNA was isolated from each 1/8 segment of a 1.5 cm² ANB card; 50 ng or approximately 8,300 cell equivalents, was used in repeat PCRs. Sensitivity was established with each PCR assay using a dilution series of patient DNA. Appropriate precautions, including the use of positive displacement pipettes, separate laboratory areas for DNA isolation, first and second round PCR set-up, and the use of multiple controls were instituted during ANB card backtracking.

Long interspersed nuclear element methylation analysis. A TaqMan long interspersed nuclear element (LINE) methylation assay, as previously described by Weisenberger and colleagues, was used with some modification (33). AluC4 was used as the DNA input control, and an assay targeting the bisulfite product of methylated LINE-M1 sequence was used as the test reaction. DNA was isolated from 51 ANB card DNA samples, 35 derived from children who contracted leukemia (10 TEL-AML1+), and 25 non–TEL-AML1 childhood acute lymphoblastic leukemias) and 19 frequency-matched by age, race, and ethnicity to the case ANB cards. All cards were provided by the California Genetic Diseases Branch (Department of Health Services) at the same time and were processed and stored under identical conditions. Guthrie card DNA samples were coded and randomized prior to analysis. One micrograms of DNA (Qiagen Micro kit, blood card protocol) was treated with bisulfite (Zymo Research). Whole genome–amplified DNA and “CpGenome” universal methylated DNA (Zymo) were treated with the same reagent and method and used as the negative and positive controls of the methylation assay, respectively. A plasmid-containing target sequence for the LINE1-M1 and AluC4 TaqMan reactions was used at the concentrations of 3.0, 0.5, 0.05, 0.005, 5 × 10⁻⁷, 5 × 10⁻⁸, 5 × 10⁻⁹, and 5 × 10⁻⁷ ng/μL to set up standard curves. Primers and probes are listed in Supplementary Table S1. In a 10 μL reaction, 1 μL of plasmid standard or treated ANB card DNA (10 ng measured prebisulfite treatment) DNA was run with 3.5 pmol/L of each primer, 1 pmol/L of probe, TaqMan master mix, in an ABI 7900 HT PCR machine:95°C for 10 min, 50 cycles at 95°C for 15 s, 53°C for 1 min. All DNA samples were run in duplicate on a 384-well plate. The results are shown as precalculated mean quantity (Mean Qty) for the duplicate sample data. The percentage methylated reference (PMR) of each sample was calculated using the following equation: PMR = [(Mean Qty of sample using LINE1-M1 primers) / (Mean Qty of sample using AluC4 primers)] / [(Mean Qty of universal methylated DNA sample using LINE1-M1 primers) / (Mean Qty of universal methylated DNA sample using AluC4 primers)] × 100.

Breakpoint motif analysis. Statistical analysis of DNA breakpoints was performed using custom script commands in the statistics environment R. Repeats were determined by RepeatMasker (version 3.1.3, February 2006 version). Differences between TEL-AML1 and del(12p) breakpoints with regard to proximity to repeats was determined using Fisher's exact test. Statistical analysis of proximity of various features (searched using EMBoss/Fuzznuc or custom perl scripts) including repeat regions (such as SINE, LINE, LTR, transposon fossils, and simple repeats), putative matrix attachment regions (34), topoisomerase II sites (35), and pyrimidine tracts (36) was performed by comparing the observed proximity of breakpoints to these features to 200 random simulations of the dispersal of breakpoints and the features within the space of the target TEL and AML1 introns. This analysis was not possible for the 12p deletions that occur on a much larger and variable scale. LINE methylation data were log₂-transformed and analyzed using Student’s t test and ANOVA, and box and whisker plots were used for visualization.

Results

Seven of 10 patients in this study presented with a “normal” 46-chromosome Gbemsa-banding karyotype. Patient no. 5 had 46 chromosomes in eight of nine mitoses, and 45 (lacking chromosome 20) in one of nine mitoses. Karyotype analysis failed in
patient nos. 3 and 7 due to lack of cell growth. All patients showed TEL-AML1 translocation by fluorescence in situ hybridization (FISH) using conventional probes (Vysis), and 9 of 10 had a deletion of the second TEL allele in the same FISH analysis.

In order to track and sequence large-scale deletions, identification of breakpoints requires kilobase-level precision rather than the hundred-kilobase resolution common with most comparative genomic hybridization (CGH) methods. This proved to be feasible using a microarray method (37), which we used to tile long isothermal oligonucleotides along the 38 Mb p-arm of chromosome 12 (37). Four of the 10 breakpoints showed apparent interstitial deletions (patients 1, 3, 4, and 5). Five showed single breakpoints with the deletion of the remainder of the chromosome arm (Fig. 1A). A single patient who did not harbor a 12p deletion by FISH using a TEL probe (Vysis; patient no. 6) did not harbor any copy number changes in 12p. The patient with the lowest proportion of del(12p)-positive TEL-AML1 cells in FISH assays [patient no. 2, 70% of TEL-AML1 cells had del(12p)] also displayed the weakest copy number loss “log 2 ratio” (Fig. 1). For this and the other eight samples, we believe the del(12p) shown is the dominant leukemic clone. The smallest “commonly deleted region” was defined by patients 3 and 4, centromeric and telomeric sides, respectively. This region was bound at positions 11,918 and 13,119 kb and contained 11 genes, including the telomeric half of TEL (exons 6–8, see Fig. 1B). Using the high-density probe design, zoomed views of the apparent breakpoints allowed for subkilobase resolution of breakpoints in some cases, or at least estimations within 10 kb (Fig. 2). Several common copy number polymorphisms were also evident in the array CGH such as a deletion polymorphism at ~32 Mb position, which was evident in patient nos. 1, 3, 5, 7, 8, and 9. Note that a common normal reference DNA was used in the array CGHs for all patients, not individually matched constitutive DNAs.

Following the fine mapping of breakpoints, we used LD-PCR or LDI-PCR to sequence fusion junctions. We used nested PCR for two reasons: to increase the specificity of PCR reactions, and to increase the amount of PCR product for sequencing purposes. Despite the appearance of interstitial deletions in four patients on the microarray, only two could be sequenced using conventional LD-PCR across the deletion (nos. 5 and 8). Patient no. 5 had a clean deletion with no intervening sequence (Fig. 2A). Patient no. 8 did not have a simple interstitial deletion but rather a portion of chromosome 5 and an inverted portion of chromosome 12 obtained within the PCR product anchored by primers surrounding the interstitial deletion.

Figure 1. A, array CGH of chromosome 12 p-arm. Isothermal tiling path array with 390,000 probes spaced at 50-bp intervals. Log 2 fluorescence ratios on Y-axis, tumor DNA (vertical up) vs. normal control (vertical down) on the Y-axis; change point analysis, TEL gene location indicated by vertical lines at 12Mb position.
B, smallest commonly deleted region on chromosome 12 from 10 patients; genes located within this region (right).
When patients exhibited terminal deletions on the microarray (nos. 2, 7, 8, 9, and 10; Fig. 1), we assumed that some non-chromosome 12 sequence, or telomere, would "cap" the shortened chromosome. We used PCR methodology that would detect either of these options, but found that in all cases, a sequence from another chromosome was involved. Chromosomes 2, 4, 5, 9, 12, 13, and 19 were involved in breakpoints for various patients (Table 1). Although in many cases, retrotransposon sequences were found at or near fusions, in all cases, we were able to make high-quality BLAST matches to these partner chromosomes by fully sequencing inverse PCR products. In no case were these translocations predicted to form an in-frame fusion gene or the aberrant juxtaposition of a promoter region to another gene (Table 1). None of these translocations involved the TEL gene, and all were confirmed using independent PCR reactions, with appropriate controls to confirm that they are specific to the leukemic clone. There were no recurrent patterns to the translocation breakpoints, and karyotypic analysis did not indicate any balanced translocations. Fine mapping of the breakpoints indicated that two breakpoints contained microhomologies (22%), and five contained nontemplate (N) nucleotides (56%, Supplementary Fig. S1). Two other breakpoints, both from patient no. 8, were clean blunt-ended fusions (Supplementary Fig. S1). Attempts at sequencing breakpoints in patient nos. 3, 4, and 7 were not successful. In the case of patient no. 4, the attempt to clone del(12p) resulted in sequencing the TEL-AML1 translocation and its reciprocal (data not shown).

Backtracking of patient breakpoints was performed using similar methodology as backtracking of the translocations in previous reports, with similar levels of sensitivity (3, 4). Two breakpoints were analyzed for two patients, and one for the
Figure 2  Continued.

Etiology of del(12p) in TEL-AML1 Leukemia
remaining four patients (Table 1). Patient no. 8 exhibited a "weak" band on an electrophoretic gel after the second round of PCR that was not the correct sequence of the breakpoint fusion. A second PCR did not yield this band. In addition, a second deletion junction from this patient was also tested by Guthrie card PCR and yielded no band. We classified this patient with the others as "negative" for the presence of del(12p) at birth. In contrast with TEL-AML1 translocation, del(12p) did not backtrack to birth in any patients. Results for some backtracking assays are displayed in Fig. 3.

The del(12p) rearrangements were highly associated with interspersed repeat regions when compared with TEL-AML1 translocations \( (p = 0.00009; \) Supplementary Table S2 and S3; Fig. 4). This association disappeared when the window of inquiry around the breakpoint was increased to 500 bp \( (p = 0.7; \) Supplementary Table S3), suggesting that there is no overall difference in retrotransposon sequence in the vicinity of TEL-AML1 fusion breakpoints compared with del(12p) breakpoints. The TEL and AML1 introns do have fewer DNA repeats (28\% and 23\%, respectively) when compared with the genome (45\%). However, there was no association with these intronic repeat regions in the TEL and AML1 introns at any higher frequency than would be expected at random \( (p = 0.7). \) In addition, TEL and AML1 breakpoints were not associated with other specific features thought to be involved in some translocations, including scaffold attachment regions, mammalian topoisomerase II sites, and polypyrimidine tracts (data not shown). In addition to this, scanning of TEL-AML1 and del(12p) breakpoints for heptamer-nonamer recombination site sequences (38) yielded no matches to patient breakpoints (data not shown). To explore whether a defect of a constitutive methylation of retrotransposon elements might contribute to instability and del(12p), we used a real-time "MethyLight" assay to quantify methylation status at LINE-M1 elements. There are more than 200 LINE elements in this family scattered around the genome and chromosome 12 has an average prevalence of these elements. This assay was chosen because it has a high correlation with global DNA methyl-cytosine content (measured by high-performance liquid chromatography; ref. 33) which reflects the presence of methyl groups in cytosines on repetitive DNA elements such as retrotransposon fossils. ANB card DNA from TEL-AML1 patients harbored significantly higher methylation status than ANB card DNA derived from children who did not contract leukemia \( (p = 0.01, \) Student’s \( t \) test; Fig. 5). Common acute lymphoblastic leukemia patients (CD19+, CD10+) that did not have TEL-AML1 also had a higher median value of LINE1-M1 methylation but when compared with control children, did not reach statistical significance \( (p = 0.052, \) \( t \) test).

### Table 1. Details of nine del(12p) breakpoints sequenced in six t(12;21)+ patients, and results of backtracking in archived newborn bloods

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age at diagnosis</th>
<th>Breakpoint junctions*</th>
<th>Genes on partners†</th>
<th>DNA aliquots tested‡</th>
<th>Limit of sensitivity§</th>
<th>Del(12p) result¶</th>
<th>TEL AML1 result‖¶</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3.1</td>
<td>Chr2: 18566233 Chr12: 17381863</td>
<td>None</td>
<td>4</td>
<td>100 pg</td>
<td>Neg.</td>
<td>nt</td>
</tr>
<tr>
<td>2</td>
<td>1.9</td>
<td>Chr9: 4596202 Chr12: 17262923 C9orf68</td>
<td>None</td>
<td>nt</td>
<td>nt</td>
<td>nt</td>
<td>na</td>
</tr>
<tr>
<td>5</td>
<td>3.5</td>
<td>Chr12: 10651543 Chr12: 13116973 MAGOH KIAA1467</td>
<td>None</td>
<td>4</td>
<td>10 pg</td>
<td>Neg.</td>
<td>Pos.</td>
</tr>
<tr>
<td>8</td>
<td>6.7</td>
<td>Chr12: 14332542 Chr5: 15571213 None FBXL7 FBXL7</td>
<td>None</td>
<td>2</td>
<td>100 pg</td>
<td>Neg.</td>
<td>Pos.</td>
</tr>
<tr>
<td>9</td>
<td>2.4</td>
<td>Chr13: 30225331 Chr12: 28980372 ALOX5AP</td>
<td>None</td>
<td>nt</td>
<td>nt</td>
<td>nt</td>
<td>na</td>
</tr>
<tr>
<td>10</td>
<td>3.1</td>
<td>Chr19: 17983155 Chr12: 29334763 ABRDC2 OVCH1</td>
<td>None</td>
<td>3</td>
<td>100 pg</td>
<td>Neg.</td>
<td>Neg.</td>
</tr>
</tbody>
</table>

*Breakpoint location on the indicated chromosome, using Human Genome v18.
†Genes located at the breakpoint on the left, and right breakpoint, respectively. "None" indicates that the breakpoint was not within a gene; all genic breakpoints were located within introns and would not be predicted to form an "in frame" fusion gene in the cases where both partner breakpoints were located within genes (patients 5, 8, and 10).
‡The number of 50-ng aliquots of purified DNA from Guthrie cards.
§The lowest level of diagnostic DNA detectable in a two-round PCR reaction.
¶Neg, no presence of breakpoint DNA by PCR; Pos, positive presence of breakpoint sequence; nt, not tested due to limited DNA from the Guthrie card; na, not applicable (only one TEL-AML1 breakpoint per subject).
‖Data from McHale et al. (3).
**Breakpoint not backtracked.
Discussion

Among the common childhood acute leukemias, those with TEL-AML1 translocations are the best characterized in terms of the natural history of leukemogenic events. In this report, we explore the timing and structure of a proposed “secondary” event—deletion of the p-arm of chromosome 12. We have found no evidence for prenatal origin of del(12p) breakpoints. Despite the small number of patient samples tested here, the result marks a strong contrast to the TEL-AML1 translocation, which we have found to be prenatal in 14 of 24 cases tested (58%; refs. 3, 4). Two of these patients who previously showed prenatal TEL-AML1 did not have the presence of the del(12p) at birth (at similar sensitivity levels); therefore, our results are quite consistent with the proposed two-hit model for this subtype of leukemia (4, 12).

TEL-AML1* leukemia is characterized by a pre-B cell phenotype and high activity of recombinase-activating gene components as exemplified by the continuous rearrangements of IGH, IGK, and IGL, as well as ectopic rearrangements of TCR loci (23–25). Despite this, we and others have found no evidence for a causal role of RAG activity in TEL-AML1 translocations. Such evidence would consist of recombinase site sequences, N-nucleotides, or other features commonly seen with RAG-associated fusions in the lymphoid neoplasms (26, 27, 39). The translocation may occur prior to the activation of RAG and TdT. As the rate-limiting event in leukemia with TEL-AML1, we hypothesized that del(12p) might take place in an ontologically similar cell type as presents with the diagnosis of leukemia and may be caused by RAG activity. In support of this, the del(12p) breakpoints displayed the presence of nontemplate nucleotides at most breakpoints (5 of 9) although this is a rare feature of TEL-AML1 translocations (only 5 of 53, 9%; P = 0.004 for the difference, Fisher’s exact test). This would suggest the formation of del(12p) at a time when terminal deoxynucleotidyl transferase was active. The breakpoints did not, however, coincide with recombinase site sequences, which are a feature of RAG-mediated recombination. This does not entirely rule out RAG involvement, as structural features including the propensity to form single-strand or hairpin structures are known targets of RAG activity. Such structures can form within retrotransposon sequences (40, 41).

The robust presence of interspersed repeat regions (particularly LINE and SINE) at the del(12p) breakpoints (Fig. 4; Supplementary Tables S2 and S3) suggests two possibilities—first, that homologous recombination of such sequences was responsible for the repair of DNA breaks, or that these sequences are inherently more prone to DNA breaks. The first of these mechanisms was ruled out because none of the breakpoint fusions were products of homologous recombination. Instead, breakpoints display features of nonhomologous end-joining (NHEJ). Features of NHEJ junctions include lack of extensive homology at breakpoints or the presence of 1 to 8 bp microhomologies. Microhomology is present at 2 del(12p) breakpoints, and blunt end-joining in all the remainder. Instead, retrotransposons may be more prone to breakage than the rest of the genome. Transposon-derived repeats make up close to 46% of the genome (42). These sequences are heavily methylated and repressed in normal somatic tissues (43), although they are often aberrantly hypomethylated in cancer (44). It is recognized that global hypomethylation of the genome is a common and possibly early event in carcinogenesis, and demethylation leads to chromosome instability in a mouse model (45). In relation to the proposed natural history of childhood leukemia presented here, activation and maturation of B cells during an infection (leading to high levels of cell division and methyl group requirements) may lead to the hypomethylation of LINE and SINE elements, DNA instability, and chromosome breaks. Ectopic expression of LINE open reading frames by demethylation in cell cultures has been shown to cause multiple double-strand breaks (46, 47). Such breaks, if aberrantly repaired by NHEJ mechanisms, could result in the type of rearrangements seen in the del(12p) rearrangements.

![Figure 3](image-url)

**Figure 3.** Electrophoretic gels of backtracking del(12p) experiments in five patients. A, secondary PCR for patient 1-F1 and 1-R1 primers. Lanes 1 and 18, 1 kb ladder; lanes 2, 3, 4, 5, 6, and 7, 100 to 0.001 ng patient 1 bone marrow serial dilution DNA; lanes 8, 9, 10, and 17, blanks; lanes 11, 12, 14, and 15, various control lymphocyte DNAs from healthy NCCLS study control participants; and lanes 13 and 16, 50 ng of patient no. 1 ANB card DNA. B, secondary PCR reaction for patient 5. Primers, patient 5-F1 and R1. Lanes 1 and 18, 1 kb ladder; lanes 2, 3, 5, 6, 7, 8, and 9, 100, 10, 1, 0.1, 0.01, and 0.001 ng patient 1 bone marrow DNA; lanes 4, 10, and 11, blanks; lanes 12, 13, 15, and 16, various control DNAs from healthy controls; and lanes 14 and 17, 50 ng of patient 5 ANB card DNA. C, D, and E, patient nos. 7, 8, and 10, respectively. Lanes 2 to 7, 100 to 0.001 ng patient 1 bone marrow serial dilution DNA; lane 7, blank; lanes 8 and 9, DNA from healthy controls; lane 10, DNA from a control ANB card; and lane 11, 50 ng of DNA from the interrogated patient’s ANB card. The primary PCR reaction is shown along with the secondary reaction (C). Gels A and B were performed by a different technician compared with gels C to E.
seen here. To explore further, we used a previously validated assay of global LINE methylation status with the hypothesis that children with lower methylation in LINE elements may be predisposed to del(12p) and leukemia. Remarkably, we found a significant association in the reverse direction: children with TEL-AML1+ leukemia are born with higher LINE1-M1 methylation than children who do not contract leukemia (see Results and Fig. 5). This conclusion, whereas exploratory and needing confirmation, suggests that methylation of LINE is deregulated in these individuals, or that the heavier methylation status is a reflection of prior or continuous ectopic activation of LINE elements leading to heavier methylation status. Younger and active LINE elements are known to be more heavily methylated than older LINE fossils that have mutated due to genetic drift (48); heavier methylation of LINE elements in a genome may be a reflection of more active retrotransposon activity. This result demands further investigation and serves a purpose here to identify a potential constitutive defect among children who contract leukemia with TEL-AML1. Because it is estimated that only 1 of 100 children born with TEL-AML1 progress to disease (9), the LINE methylation defect indicated here is a candidate risk factor for leukemia progression, which must be confirmed in population-based studies. To be sure, it should be

Figure 4. Schematic representation showing the proximity and identity of repetitive elements in relation to the patient breakpoints. Alu sequences (black), LINE elements (cross-hatched rectangles), and long terminal repeat sequences (open rectangles). The breakpoints are listed (a, b, c . . .) from left to right in relationship to the chromosome 12 arm (see Supplementary Table 2 for the data that this figure is based on).
noted that chromosome 12 harbors an average frequency of LINE1-M1 elements; our assay assessed genome-wide methylation rather than chromosome or locus-specific methylation levels.

It should also be noted that TEL-AML1 protein targets transcriptional repression via histone deacetylase (49), a process that can precede CpG methylation (50, 51). This specific promoter methylation activity is independent of processes that lead to global DNA methylation at retrotransposons. TEL-AML1 is a prenatal event in most leukemia cases, but the TEL-AML1+ clone is not likely to affect the ANB card LINE methylation result because those cells represent a small minority of assayed cells on a card (>1%).

Our analysis of del(12p) breaks does not exclude TEL as the target; all patients exhibited a deletion of at least a portion of the TEL gene. A single individual harbored a deletion of the last three exons of TEL but this was likely a rearrangement on the cis chromosome (patient 4); this patient's del(12p) was not sequenced. Whether any other gene within the commonly deleted region (Fig. 1B) is also critical will require the addition of alternative patient samples with a similar techniques as well as gene function studies. Current microarray methods have not ruled out every gene in the region for all patients.

In sum, the sequencing and backtracking of del(12p) rearrangements has provided additional support for the Greaves "two-hit hypothesis," which posits that this "second" or rate-limiting mutation in this type of leukemia subtype is postnatal and could arise from aberrantly strong immunostimulation that occurs during an infection proximal to the leukemia diagnosis (52). An unexpected association of these rearrangements with SINE and LINE retrotransposons in the human genome suggests that they may contribute to its formation. Finally, the data is compatible with the hypothesis that these rearrangements occur at an ontologically more mature cell than the TEL-AML1 translocation.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 6/9/2008; revised 8/26/2008; accepted 9/3/2008.

Grant support: NIH CA89032 (J.L. Wiemels), P42-ES04705 (M.T. Smith) and R01 ES09137 (P.A. Buftler), the Children with Leukemia Fund, UK (J.L. Wiemels and P.A. Buftler), and FAMRI YCSA (C.J. Maris).

References

2. Burjanivova T, Madzo J, Muzikova K, et al. Prenatal origin of chromosome 12 harbors an average frequency of LINE1-M1 elements; our assay assessed genome-wide methylation rather than chromosome or locus-specific methylation levels.